BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Industry: Healthcare

OFF LIST - 1231 consecutive market days: OFF LIST as of 07/15/2011 Through 11/14/2016

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Current Quote*
Last: $59.365
Change: 1.105
Book: $5.240
Volume: 35,399

As Of: 11/14 14:20 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol BSTC

Graphs for BSTC

3 Month Graph

6 Month Graph

1 Year Graph